Accessibility Menu
Indivior Plc logo

Indivior Plc(NASDAQ) INDV

Current Price$40.44
Market Cap$5.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+291%
5 Year+284%
1 Year+139%
1 Month+1%
Indivior Plc last closing stock price
MetricPriceDate
Last closeUSD 40.512026-07-23
Indivior Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.2%USD 40.592026-07-16
1 month+1.38%USD 39.962026-06-23
3 month+21.91%USD 33.232026-04-24
Year to date+12.9%USD 35.882025-12-31
1 year+139%USD 16.952025-07-23
3 year+69.19%USD 23.942023-07-24
5 year+283.98%USD 10.552021-07-22
Since inception+291.43%USD 10.332014-12-29

Indivior Plc Financials at a Glance

Market Cap

$5.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.29B

Net Income (TTM)

$251.00M

EPS (TTM)

$1.97

P/E Ratio

20.52

Dividend

$0.00

Beta (Volatility)

0.25 (Low)

Price

$40.44

Volume

2,386,618

Open

$39.81

Previous Close

$40.51

Daily Range

$39.65 - $40.71

52-Week Range

$16.69 - $42.81

Estimated Earnings Date

Jul 30, 2026

About Indivior Plc

Indivior PLC focuses on developing treatments for addiction, emphasizing opioid dependence therapies. The company's strong reputation stems from its pioneering work in this crucial healthcare segment. By specializing in this niche, Indivior PLC addresses global public health issues related to addiction, particularly opioid dependence.

Products and Services

Suboxone: A medication-assisted treatment for opioid dependence.

Subutex: Another therapeutic option for opioid addiction management.

Perseris: A treatment for schizophrenia, expanding the company’s reach into mental health.

What Makes Indivior PLC Special

Indivior PLC stands out through its focus on opioid dependence treatments, backed by a strong portfolio of patented products. The company’s commitment to innovative research and development provides a substantial competitive edge. Through strategic leadership and industry expertise, Indivior continues to enhance its offerings for addiction treatment.

Five Things You Need to Know

Indivior PLC is a leader in opioid addiction treatments, addressing a critical global health issue.

Suboxone, a key product, has built a strong reputation for efficacy and safety.

Continuous innovation in its product lineup supports long-term company growth.

Strategic expansion into new markets aims to increase the company’s global footprint.

Indivior emphasizes sustainability and patient-centric care as a core business strategy.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Employees

838

CEO

Joseph J. Ciaffoni, MBA

Headquarters

North Chesterfield, VA 23235, US

INDV Financials

Key Financial Metrics (TTM)

Gross Margin

83.11%

Operating Margin

33.31%

Net Income Margin

19.44%

Return on Equity

-142.01%

Return on Capital

104.74%

Return on Assets

20.97%

Earnings Yield

4.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

124.77M

Volume

2.39M

Avg. Volume

2.02M

Financials (TTM)

Gross Profit

$1.07B

Operating Income

$430.00M

EBITDA

$352.00M

Operating Cash Flow

-$102.96M

Capital Expenditure

-$81.66M

Free Cash Flow

-$184.62M

Cash & ST Invst.

$175.00M

Total Debt

$509.00M

Indivior Plc Performance Analysis

Indivior Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 901,000,00013.9%
20232023-12-31USD 1,093,000,00021.3%
20242024-12-31USD 1,188,000,0008.7%
20252025-12-31USD 1,239,000,0004.3%
Indivior Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3013.5%
Q32025-09-304.0%
Q42025-12-3114.0%
Q12026-03-31-11.5%
Indivior Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.38N/A
20232023-12-31USD -0.94146.9%
20242024-12-31USD 0.05N/A
20252025-12-31USD 1.643019.0%
Indivior Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-63.2%
Q32025-09-30135.7%
Q42025-12-31148.5%
Q12026-03-31-15.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$317.00M

+19.2%

Gross Profit

$277.00M

+24.8%

Gross Margin

87.38%

N/A

Market Cap

$5.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.03M

N/A

Employees

838

N/A

Net Income

$89.00M

+89.4%

EBITDA

$124.00M

+63.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$175.00M

-53.1%

Total Debt

$509.00M

+37.6%

Accounts Receivable

$285.00M

+17.3%

Inventory

$152.00M

-6.7%

Long Term Debt

$500.00M

+46.6%

Short Term Debt

$9.00M

-69.0%

Return on Assets

20.97%

N/A

Return on Invested Capital

1.03%

N/A

Free Cash Flow

-$29.00M

-141.4%

Operating Cash Flow

-$9.00M

-112.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMRXAmneal Pharmaceuticals, Inc.
$17.97+1.24%
ACADACADIA Pharmaceuticals Inc.
$24.83-0.52%
HNGEHinge Health, Inc.
$76.69-3.02%
VKTXViking Therapeutics, Inc.
$35.39-5.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
NOKNokia
$9.73-0.05%
INTCIntel
$100.23-0.02%
AALAmerican Airlines Group
$13.56-0.08%

Questions About INDV

What is the current price of Indivior Plc?

Indivior Plc is trading at $40.51 per share.

What is the 52-week range for Indivior Plc?

Over the past 52 weeks, Indivior Plc has traded between $16.69 and $42.81.

How much debt does Indivior Plc have?

As of the most recent reporting period, Indivior Plc reported total debt of $509.00M.

How much cash does Indivior Plc have on hand?

Indivior Plc reported $175.00M in cash and cash equivalents in its most recent financial results.

What is Indivior Plc’s dividend yield?

Indivior Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.